Affiliation:
1. P.A. Gertsen Moscow Research Cancer Institute – branch of the National Medical Research Radiology
Center
2. Clinical Hospital Lapino
Abstract
Although significant advances have been made in breast cancer treatment resulting in improved survival, cardiovascular disease has become the main cause of disability and mortality not related to cancer recurrence. In the general population, cardiovascular disease is the leading cause of death in both women and men. In patients with breast cancer, the incidence of cardiovascular diseases is even higher than in the general population. The high incidence of cardiovascular disease in breast cancer patients is likely due to the presence of common risk factors as well as the patients with breast cancer, the incidence of cardiovascular diseases is even higher than in the general population. The high incidence of cardiovascular disease in breast cancer patients is likely due to the presence of common risk factors as well as cardiotoxicity of anticancer therapy. The rise in the development of cardiovascular disease in breast cancer survivors is a major concern. This literature review will describe the incidence of cardiovascular complications with different treatment regimens for breast cancer, risk factors for their development, strategies for monitoring cardiovascular function during and after anticancer therapy, and strategies for the prevention and treatment of cardiotoxicity.
Publisher
Tomsk Cancer Research Institute
Reference59 articles.
1. Bradshaw P.T., Stevens J., Khankari N., Teitelbaum S.L., Neugut A.I., Gammon M.D. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology. 2016 Jan; 27(1): 6–13. doi: 10.1097/EDE.0000000000000394.
2. Park N.J., Chang Y., Bender C., Conley Y., Chlebowski R.T., van Londen G.J., Foraker R., Wassertheil-Smoller S., Stefanick M.L., Kuller L.H. Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women’s Health Initiative. PLoS One. 2017 Sep 21; 12(9): e0184174. doi: 10.1371/journal.pone.0184174.
3. Polk A., Shahmarvand N., Vistisen K., Vaage-Nilsen M., Larsen F.O., Schou M., Nielsen D.L. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open. 2016 Oct 19; 6(10): e012798. doi: 10.1136/bmjopen-2016-012798.
4. National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Female Breast Cancer [Internet]. URL: https://seer.cancer.gov/statfacts/html/breast.html (cited 9.10.2018).
5. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov; 18(11): 1639–42. doi: 10.1038/nm.2919.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献